If pancreatic cancer can be surgically resected, a significant proportion of patients can be cured, and the 5-year survival rate can reach 15%-20%, and in the case of patients with earlier stage I cancer, the 5-year survival rate can even reach 40%. Therefore, surgical resection is definitely the preferred treatment for pancreatic cancer, but unfortunately, due to the lack of effective early diagnosis methods, up to 60%-80% of patients are already beyond surgical resection when pancreatic cancer is detected. First of all, we should confirm whether the patient is suffering from pancreatic cancer or not? In other words, a clear diagnosis of pancreatic cancer should be made. At present, the diagnosis of pancreatic cancer mainly relies on the following means: serological diagnosis by tumor markers such as CA199; imaging diagnosis by pancreatic thin-section CT and MRI; functional imaging diagnosis by PET-CT. However, to confirm the diagnosis of pancreatic cancer, it is necessary to obtain a pathological diagnosis, which requires performing ultrasound endoscopy or CT localization puncture. Obtaining a pathological confirmation of the diagnosis also allows the staging of the cancer to guide the next treatment, such as the treatment of ductal adenocarcinoma and neuroendocrine carcinoma of the pancreas is completely different. After the diagnosis of pancreatic cancer is confirmed, we have to make a reasonable individualized treatment plan according to the patient’s general condition and laboratory indexes, and the aim of treatment is to prolong the patient’s survival period and improve the patient’s quality of life as much as possible. Here we take the most common pancreatic ductal adenocarcinoma as an example: 1. If the patient is in good general condition, it is recommended to choose chemotherapy first. Chemotherapy is the most effective treatment for pancreatic cancer other than surgical resection. Currently, the commonly used chemotherapy drugs for pancreatic cancer include: gemcitabine, tegeo, albumin nanoparticles paclitaxel; in addition, 5-Fu, platinum, irinotecan, etc. can also be used. Gemcitabine is the most classic chemotherapy drug for pancreatic cancer in the past 20 years; Tegeo was first used for gastric cancer, and its efficacy in pancreatic cancer has been found to be no worse than that of gemcitabine in the past 5 years, and it can be used orally; albumin nanoparticle paclitaxel has been used for pancreatic cancer in the past 3 years, and its efficiency in combination with gemcitabine is double than that of gemcitabine alone, but the disadvantage is that it is expensive. 2.If the patient has more obvious pain symptoms, radiotherapy can be considered. Due to the deep anatomical position of the pancreas in the human body, there are many organs in front and around which are sensitive to radiation, while pancreatic cancer itself is not sensitive to radiation, so the early general external radiation radiotherapy is not effective and has many side effects. In recent years, with the improvement of radiotherapy technology and the application of various radiotherapy methods, such as intraoperative radiotherapy through minimally invasive laparoscopy, stereotactic three-dimensional conformal radiotherapy and simultaneous radiotherapy and chemotherapy instead of simple radiotherapy, the local control rate of pancreatic tumors has been greatly improved, and radiotherapy has obvious effects on improving the pain symptoms of patients. 3.A portion of patients who are critically resectable can also regain the opportunity of surgical resection through neoadjuvant chemotherapy or radiotherapy. 4.If the patient already has jaundice when pancreatic cancer is discovered, it is recommended to first reduce the yellowing treatment. ERCP is to support a stent at the lower end of the obstructed common bile duct through endoscopy, which has the advantage of bile entering the intestine to help digestion, and no drainage tube outside the body, so the patient has a high quality of life. PTCD is to drain the bile ducts above the obstruction site by percutaneous hepatic puncture, the advantage is the exact bile drainage, the disadvantage is the bile drainage outside the body, which affects the digestive function, and there is a drainage tube outside the body, which affects the patient’s quality of life, of course, if possible, a stent can be placed through the PTCD drainage tube; if either ERCP or PTCD is inoperable or the result is not good, sometimes we are forced to reduce the yellowing surgically. If ERCP or PTCD cannot be operated or the result is not good, sometimes we are forced to reduce the yellowing surgically. 5.If pancreatic cancer is found to be accompanied by gastrointestinal obstruction, that is, inability to eat and vomiting, it is recommended to remove the gastrointestinal obstruction first. At present, the main methods of relieving GI obstruction include: bypass surgery and GI stenting. Bypass surgery alone is not very traumatic and has definite efficacy, and if jaundice is present, it can also reduce the yellowing at the same time; however, if the patient’s general condition is poor and cannot tolerate the surgery, he has to choose GI stenting, with the disadvantage of certain risk of GI perforation and bleeding. 6.In addition to chemotherapy and radiotherapy, some other adjuvant treatments can also be used. At present, the efficacy is more accurate: local treatment for liver metastases (such as radiofrequency), immunotherapy, biological treatment and Chinese herbal medicine’s corrective treatment. 7, symptomatic supportive treatment: for those who have steatorrhea due to pancreatic exocrine insufficiency, pancreatic enzyme preparations can be taken to help digestion; for intractable pain, analgesic drugs should be used reasonably, and if necessary, ethanol should be injected into the abdominal plexus to reduce the patient’s pain; nutritional support should also be strengthened to improve the nutritional status.